Randall J. Bateman

51.3k total citations · 18 hit papers
249 papers, 19.5k citations indexed

About

Randall J. Bateman is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Randall J. Bateman has authored 249 papers receiving a total of 19.5k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Physiology, 111 papers in Psychiatry and Mental health and 73 papers in Molecular Biology. Recurrent topics in Randall J. Bateman's work include Alzheimer's disease research and treatments (164 papers), Dementia and Cognitive Impairment Research (107 papers) and Cholinesterase and Neurodegenerative Diseases (23 papers). Randall J. Bateman is often cited by papers focused on Alzheimer's disease research and treatments (164 papers), Dementia and Cognitive Impairment Research (107 papers) and Cholinesterase and Neurodegenerative Diseases (23 papers). Randall J. Bateman collaborates with scholars based in United States, United Kingdom and Sweden. Randall J. Bateman's co-authors include John C. Morris, David M. Holtzman, Kwasi G. Mawuenyega, Vitaliy Ovod, Kevin E. Yarasheski, Tom Kasten, Ling Y. Munsell, Wendy Sigurdson, Kaj Blennow and Reisa A. Sperling and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Randall J. Bateman

234 papers receiving 19.2k citations

Hit Papers

Lecanemab in Early... 2009 2026 2014 2020 2022 2010 2015 2009 2011 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lecanemab in Early Alzheimer’s Disease
    2022 2.7k citations Randall J. Bateman et al. profile →
  2. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
    2010 1.6k citations Kwasi G. Mawuenyega, Wendy Sigurdson et al. Science profile →
  3. Alzheimer's disease
    2015 1.3k citations Randall J. Bateman, Kaj Blennow et al. profile →
  4. Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle
    2009 1.2k citations Miranda M. Lim, Randall J. Bateman et al. Science profile →
  5. Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance
    2011 887 citations Jungsu Kim, Bruce W. Patterson et al. profile →
  6. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
    2019 551 citations Suzanne E. Schindler, James G. Bollinger et al. profile →
  7. Tau Kinetics in Neurons and the Human Central Nervous System
    2018 397 citations Chihiro Sato, Nicolas R. Barthélemy et al. profile →
  8. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
    2017 386 citations Vitaliy Ovod, Kwasi G. Mawuenyega et al. Alzheimer s & Dementia profile →
  9. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
    2021 267 citations Shorena Janelidze, Henrik Zetterberg et al. JAMA Neurology profile →
  10. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
    2020 265 citations Nicolas R. Barthélemy, Kanta Horie et al. profile →
  11. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
    2022 242 citations Shorena Janelidze, Nicolas R. Barthélemy et al. profile →
  12. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
    2022 185 citations Eric McDade, Randall J. Bateman et al. profile →
  13. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
    2021 136 citations Tim West, Kristopher M. Kirmess et al. profile →
  14. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
    2022 127 citations Shorena Janelidze, Nicholas Cullen et al. Alzheimer s & Dementia profile →
  15. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
    2023 77 citations Shorena Janelidze, Nicolas R. Barthélemy et al. JAMA Neurology profile →
  16. Disease staging of Alzheimer’s disease using a CSF-based biomarker model
    2024 49 citations Kanta Horie, Nicolas R. Barthélemy et al. Nature Aging profile →
  17. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
    2024 42 citations Shorena Janelidze, Nicolas R. Barthélemy et al. JAMA Neurology profile →
  18. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
    2025 27 citations Kanta Horie, Shorena Janelidze et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Randall J. Bateman United States 57 12.0k 5.6k 4.9k 3.6k 2.6k 249 19.5k
Simon Lovestone United Kingdom 79 9.5k 0.8× 5.3k 0.9× 7.7k 1.6× 2.7k 0.8× 1.9k 0.7× 368 21.0k
Lan Tan China 82 9.3k 0.8× 5.1k 0.9× 6.6k 1.4× 5.5k 1.5× 1.7k 0.6× 564 24.2k
Lennart Minthon Sweden 76 11.1k 0.9× 8.3k 1.5× 4.2k 0.9× 3.8k 1.1× 2.1k 0.8× 264 18.9k
Gary W. Small United States 59 10.0k 0.8× 7.2k 1.3× 4.2k 0.9× 2.5k 0.7× 3.2k 1.2× 245 20.9k
Jin‐Tai Yu China 85 8.9k 0.7× 4.7k 0.8× 7.2k 1.5× 5.3k 1.5× 1.5k 0.6× 454 23.8k
Anne M. Fagan United States 86 15.2k 1.3× 9.5k 1.7× 6.1k 1.3× 4.9k 1.4× 5.2k 2.0× 290 26.3k
Elaine R. Peskind United States 87 7.9k 0.7× 5.6k 1.0× 4.8k 1.0× 2.8k 0.8× 2.7k 1.0× 294 23.0k
Paul Aisen United States 69 17.4k 1.4× 10.5k 1.9× 6.1k 1.2× 5.3k 1.5× 3.9k 1.5× 202 28.7k
Christopher C. Rowe Australia 73 11.8k 1.0× 10.1k 1.8× 3.6k 0.7× 2.9k 0.8× 4.0k 1.5× 439 21.6k
Dietmar Rudolf Thal Germany 60 11.5k 1.0× 4.9k 0.9× 5.1k 1.1× 4.6k 1.3× 1.7k 0.6× 234 19.1k

Countries citing papers authored by Randall J. Bateman

Since Specialization
Citations

This map shows the geographic impact of Randall J. Bateman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randall J. Bateman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randall J. Bateman more than expected).

Fields of papers citing papers by Randall J. Bateman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randall J. Bateman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randall J. Bateman. The network helps show where Randall J. Bateman may publish in the future.

Co-authorship network of co-authors of Randall J. Bateman

This figure shows the co-authorship network connecting the top 25 collaborators of Randall J. Bateman. A scholar is included among the top collaborators of Randall J. Bateman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randall J. Bateman. Randall J. Bateman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Angioni, Davide, Lefkos Middleton, Randall J. Bateman, et al.. (2025). Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force. The Journal of Prevention of Alzheimer s Disease. 12(6). 100163–100163. 2 indexed citations
2.
Llibre‐Guerra, Jorge J., Ruijin Lu, Alan E. Renton, et al.. (2024). Cognitive reserve influences symptom onset and longitudinal decline in Dominantly Inherited Alzheimer's Disease. Alzheimer s & Dementia. 20(S3). e086295–e086295.
3.
Figdore, Daniel J., Heather J. Wiste, Joshua A. Bornhorst, et al.. (2024). Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 16(1). e12545–e12545. 9 indexed citations
4.
Janelidze, Shorena, Nicolas R. Barthélemy, Yingxin He, Randall J. Bateman, & Oskar Hansson. (2023). Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios. JAMA Neurology. 80(5). 516–516. 77 indexed citations breakdown →
5.
Fogelman, I., Tim West, Joel B. Braunstein, et al.. (2023). Independent study demonstrates amyloid probability score accurately indicates amyloid pathology. Annals of Clinical and Translational Neurology. 10(5). 765–778. 13 indexed citations
6.
McCullough, Austin, Brian A. Gordon, Charles D. Chen, et al.. (2023). Evaluating Regional Importance for Tau Spatial Spread in Predicting Cognitive Impairment with Machine Learning. Alzheimer s & Dementia. 19(S24). 1 indexed citations
7.
Cullen, Nicholas, Shorena Janelidze, Erik Stomrud, et al.. (2023). Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease. Brain Communications. 5(2). fcad015–fcad015. 5 indexed citations
8.
Xu, Jinbin, Yiran Hou, Shinnosuke Yamada, et al.. (2023). Human striatal glia differentially contribute to AD- and PD-specific neurodegeneration. Nature Aging. 3(3). 346–365. 23 indexed citations
9.
Millar, Peter R, Brian A. Gordon, Patrick H. Luckett, et al.. (2023). Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study. eLife. 12. 31 indexed citations
10.
Lucey, Brendan P., Haiyan Liu, Cristina D. Toedebusch, et al.. (2023). Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS. Annals of Neurology. 94(1). 27–40. 46 indexed citations
11.
Elbert, Donald L., Bruce W. Patterson, Brendan P. Lucey, Tammie L.S. Benzinger, & Randall J. Bateman. (2022). Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways. Communications Biology. 5(1). 98–98. 39 indexed citations
12.
Tosun, Duygu, Dallas P. Veitch, Paul Aisen, et al.. (2021). Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications. 3(2). fcab008–fcab008. 53 indexed citations
13.
LaMontagne, Pamela, Matthew F. Glasser, Randall J. Bateman, et al.. (2021). Regional age-related atrophy after screening for preclinical alzheimer disease. Neurobiology of Aging. 109. 43–51. 9 indexed citations
14.
Sato, Chihiro, Elena Ficulle, Anan Yu, et al.. (2021). Recapitulation of Endogenous 4R Tau Expression and Formation of Insoluble Tau in Directly Reprogrammed Human Neurons. SSRN Electronic Journal. 5 indexed citations
15.
Barthélemy, Nicolas R., Haiyan Liu, William Lu, et al.. (2020). Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid. Annals of Neurology. 87(5). 700–709. 84 indexed citations
16.
Goyal, Manu S., Tyler Blazey, Yi Su, et al.. (2019). Persistent metabolic youth in the aging female brain. Proceedings of the National Academy of Sciences. 116(8). 3251–3255. 108 indexed citations
17.
Wildsmith, Kristin R., Jacob M. Basak, Bruce W. Patterson, et al.. (2012). Correction: In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS. PLoS ONE. 7(7). 4 indexed citations
18.
Mawuenyega, Kwasi G., Wendy Sigurdson, Vitaliy Ovod, et al.. (2010). Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease. Science. 330(6012). 1774–1774. 1637 indexed citations breakdown →
19.
Lim, Miranda M., Randall J. Bateman, James J. Lee, et al.. (2009). Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science. 326(5955). 1005–1007. 1152 indexed citations breakdown →
20.
Yin, Ke‐Jie, John R. Cirrito, Ping Yan, et al.. (2006). Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism. Journal of Neuroscience. 26(43). 10939–10948. 307 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simon Lovestone Breakdown of academic impact, for papers by Lan Tan Breakdown of academic impact, for papers by Lennart Minthon Breakdown of academic impact, for papers by Gary W. Small Breakdown of academic impact, for papers by Jin‐Tai Yu Breakdown of academic impact, for papers by Anne M. Fagan Breakdown of academic impact, for papers by Elaine R. Peskind Breakdown of academic impact, for papers by Paul Aisen Breakdown of academic impact, for papers by Christopher C. Rowe Breakdown of academic impact, for papers by Dietmar Rudolf Thal
Rankless by CCL
2026